- Home
- EML vs HURA Comparison
EML vs HURA Comparison
Compare EML & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EML | HURA |
|---|---|---|
| Founded | 1858 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.2M | 131.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EML | HURA |
|---|---|---|
| Price | $18.30 | $0.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 17.4K | ★ 458.3K |
| Earning Date | 11-04-2025 | 02-14-2026 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $258,121,226.00 | N/A |
| Revenue This Year | $1.56 | N/A |
| Revenue Next Year | $7.00 | N/A |
| P/E Ratio | $17.62 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $18.11 | $0.70 |
| 52 Week High | $29.55 | $5.50 |
Technical Indicators
Market Signals| Indicator | EML | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 38.72 | 27.87 |
| Support Level | $18.11 | $0.70 |
| Resistance Level | $19.06 | $0.78 |
| Average True Range (ATR) | 0.78 | 0.08 |
| MACD | -0.15 | 0.04 |
| Stochastic Oscillator | 3.81 | 24.05 |
Price Performance
Historical ComparisonAbout EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.